The Belgian Metabolomics Day Research at the Metabolism and Nutrition Research Group Univesité catholique de Louvain Laure Bindels, PhD Melle, Belgium September 29, 2017
Platforms for metabolomics at UCL • MASSMET – Mass spectrometry of metabolites and compounds of pharmaceutical and biological interest https://uclouvain.be/en/research-institutes/ldri/massmet.html • NEST – Nuclear & Electron Spin Technologies https://uclouvain.be/en/research-institutes/ldri/nest.html
MASSMET platform Technologies • Mass spectrometry analysis: – Mass spectrometry detection – High resolution accurate mass spectrometry – Molecular formula determination – Mass spectra data analysis • Chromatography: HPLC, UPLC & GC • Spectroscopy : UV-Vis spectrophotometry & Fluorescence spectroscopy Analyses • Lipidomics (fatty acids, bioactive lipids) • Quality control of plants and plant extracts • Essential oils Contact: Prof. Giulio Muccioli (giulio.muccioli@uclouvain.be)
NEST platform Technologies • Pre-clinical MRI and MRS • EPR spectroscopy and imaging Analyses • In vivo anatomical structures with high spatial and temporal resolution • Metabolism (spectroscopy and spectroscopic imaging) • Vessels architecture (micro-angiography) • Free radicals measurements • Free radicals characterization by spin trapping • … Contact: Prof. Bénédicte Jordan (benedicte.jordan@uclouvain.be)
Cancer cachexia • Up to 80% of cancer patients, depending of the tumor site • Reduces quality and length of life • May be a cause of cancer therapy discontinuation • No valid treatment Giacometti, Walking man Fearon et al. , Cell Metab 2012; Fearon et al., Nat Rev Oncol 2013; Argiles et al, Nat Rev Cancer 2014.
Cancer cachexia Bindels & Thissen, Clin Nutr Exp 2015
Selected synbiotic approach D0 D1 D13 † L. reuteri 100-23 ITF Bcr-Abl-expressing BaF3 cells Bindels et al, The ISME J 2016
Benefits of the synbiotic approach Bcr-Abl BaF 0.50 * # 0.45 * (relative expression) 1.0 0.40 (% body weight) Organ weight # mRNA levels 0.35 0.20 * $ 0.5 * 0.15 0.10 0.05 ND 0.0 0.00 CT BaF BaF-LrI CT BaF BaF-LrI CT BaF BaF-LrI tibialis gastrocnemius Morbidity score Survival BaF 5 1.2 BaF-LrI 1.0 4 Fraction survival p = 0.007 0.8 median survival + 2 days 3 Score # # 0.6 2 0.4 1 0.2 0 0.0 BaF BaF-LrI 0 5 10 15 20 Days after BaF injection Bindels et al, The ISME J 2016
intact BaF3/w ell control B c r - A b l BaF 1.0 � 10 7 propionate 2mM Number of 1 . 0 5.0 � 10 6 § * * Acetate ls e 0 ) n 0 . 5 v io le s 0 24 48 72 A s N re R p m x e e tiv la (re N D Propionate 0 . 0 CT BaF3 BaF3-ITF Butyrate ITF Acetate P r o p i o n a t e Propionate Butyrate § 6 0 Acetate 4 0 M µ Propionate 2 0 Butyrate 0 BaF3-ITF BaF3 CT Bindels et al, Br J Cancer 2012; Bindels*, Neyrinck* et al, Plos ONE 2015.
Ongoing work ? Dr M. Sboarina ? propionate ? RS ITF AXOS S. Pötgens POS
Production of microbial metabolites? NMR metabolomics Poster n° 5 Fed or not microbiota -targeting foods 11 Sarah Pötgens’s thesis, ongoing
Dr A. Neyrinck Prof P. Cani Prof N. Delzenne Laure Bindels Lau www.uclouvain.be/laure.bindels S. Pötgens laure.bindels@uclouvain.be UCL (BE) ULG (BE) Katholieke Universiteit University of Alberta INRA AgroParisTech (FR) Prof G. Muccioli Leuven (BE) Dr B. Taminiau (CA) Prof P. Langella and his team Prof J.P. Thissen Prof G. Daube Dr H. Schoemans Prof J. Walter Prof O. Feron Prof J. Maertens Dr I. Martinez University of Reading (UK) Prof P. Sonveaux Prof S. P. Claus and C. Leroy Dr P. Porporato Prof J.B. Demoulin Institut Pasteur, Lille (FR) Dr V. Havelange Prof B. Pot and Dr C. Grangette Dr Fl. Bindels
Recommend
More recommend
